Research Study for Grave's Disease
Official Title
A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves’ Disease
Purpose
- To find out how safe the study drug is and how well people with Graves’ disease can handle taking one or more doses.
- To describe how the body absorbs, uses, and removes a single IV or subcutaneous dose, or several subcutaneous doses, of MER511 in people with Graves’ disease.
- To check whether the body creates an immune response after a single IV or subcutaneous dose, or several subcutaneous doses, of MER511 in people with Graves’ disease.
Could this study be right for you?
- Grave's disease diagnosis
- Taking methimazole or propylthiouracil
- Weigh at least 110 lbs
- Women of childbearing potential must agree to use contraceptive methods and avoid egg donation during the study; Men with partners of childbearing potential must agree to use a condom or abstinence and avoid sperm donation during the study